RenovoRx Stockholders Approve 2 Million Share Increase for Equity Incentive Plan
RNXT sits 40% above its 52-week low of $0.701.
Summary
RenovoRx, Inc. held its annual meeting, where stockholders re-elected all directors, ratified the auditor, and approved a significant increase of 2,000,000 shares to the company's equity incentive plan.
Key Events · Corporate Governance and Compliance · RNXT
-
Equity Incentive Plan Amended
Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares of common stock. This increases the pool for future equity awards and represents approximately 4.4% of the company's outstanding shares.
-
Directors Re-elected
All six nominated directors, including Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP, were re-elected for a one-year term.
-
Auditor Ratified
Stockholders ratified the appointment of Frank, Rimerman + Co. LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Analysis · RNXT · Life Sciences
RenovoRx stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares for future equity grants. This authorization represents approximately 4.4% of the company's outstanding shares and provides significant capacity for incentivizing employees and directors. While this introduces potential future dilution for existing shareholders, it is a common and often necessary step for life sciences companies to attract and retain key talent.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNXT was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.2M. The 52-week trading range was $0.70 to $1.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.